A Randomized, Double-Blind, Parallel-Group Study to Compare Efficacy, Safety, and Immunogenicity of GME751 (Proposed Pembrolizumab Biosimilar) And Eu-Authorized Keytruda® In Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status
Active (Recruiting)
Disease
Non-Small Cell Lung Cancer
Treament Agent
GME751 (Proposed Pembrolizumab Biosimilar) vs Pembrolizumab
Study Phase
III
Resources and Links
Physician Name(s)
Dr John Low Seng Hooi
Dr Mastura Md Yusof
Dr Malwinder Singh Sandhu
Description
To demonstrate efficacy equivalence between GME751 pembrolizumab biosimilar and EU-authorized Keytruda (referred to as Keytruda-EU hereafter) in a combination with pemetrexed + carboplatin or cisplatin in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations
Cancer Type
Lung Cancer
I would like to be a part of tomorrow's breakthrough
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you:
8, Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
.webp?sfvrsn=20763f7d_21)
.webp?sfvrsn=f2a2c343_12)
